Vertex pays $4.9 Billion for Alpine Immune Science
Post# of 148110
(Total Views: 547)
Posted On: 04/13/2024 4:17:57 PM
Vertex pays $4.9 Billion for Alpine Immune Sciences...for its experimental drug Povetacicept... to treat igA Nephropathy, a kidney disease.
As established in 2022, the igA nephropathy market in the USA was estimated to be about $160 million and projected to be $469.283 million by 2028.
I.gA nephropathy is a rare disease that causes kidney damage when the body's immune system produces antibodies in the kidneys, which leads to INFLAMMATION...
Vertex at theses numbers wouldn't see profit until early 2040...that's a long play.
ohm...are you in the house?
As established in 2022, the igA nephropathy market in the USA was estimated to be about $160 million and projected to be $469.283 million by 2028.
I.gA nephropathy is a rare disease that causes kidney damage when the body's immune system produces antibodies in the kidneys, which leads to INFLAMMATION...
Vertex at theses numbers wouldn't see profit until early 2040...that's a long play.
ohm...are you in the house?
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼